Accelerating the global effort to create an AIDS vaccine: IP issues for future global public goods products

Workshop of Differential Pricing and Financing of Essential Drugs,
WHO/WTO
Norway

Dr. Seth Berkley
President & CEO
Global AIDS Goals

- **Short Term**: to prevent further spread of the virus, to treat those that are infected and to mitigate the societal consequences of infection

- **Long Term**: to create the tools necessary to end the epidemic
Five years ago (circa 1996)

- Vaccine pipeline limited
- Little investment in products by public or private sectors (market failure)
- Little public interest in HIV vaccines
- No vaccine ever tested for efficacy
- Limited attention to vaccine issues specific to high incidence countries
- Few vaccine advocates
Today

- Pipeline is more robust (depth & breadth)
- Industry coming back in with shareholder’s resources
- First vaccine efficacy testing about to be completed
- Enhanced efforts by public sector institutions
  - NIH, EC, WRAIR, ANRS, UNAIDS/WHO
- New Players & models
  - VRC, Waterford Project, IAVI
- Political leadership is clearly stronger
Different Challenges in 2001

- Consolidate gains in pipeline (assure breadth and depth of approaches)
  - Solve neutralizing antibody problem
- Focus on critical needs of high incidence countries
- Assure access policies, delivery systems and adequate manufacturing are/will be in place
- Provide incentives for further pharmaceutical company investments and protect their primary markets
- Speed matters with HIV—10 new infections a minute therefore: Speed, Speed, Speed…
IAVI’s New Vision - requires dual commitment

Private Sector Responsibilities - Supply life-saving patented drugs & vaccines to the very poor at cost plus (immediately); differential pricing for other groups based upon ability to pay

Public Sector Responsibilities – Protect primary markets, protect IP, assure no parallel trade back to OECD, finance R&D for products with poor commercial potential, provide finance & distribution systems for getting these products to those who need them, help with industrial scale up if necessary
IAVI’s mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
IAVI’s Four Strategies

- **Build worldwide demand & support for HIV vaccines**

- **Push:** Accelerate scientific progress

- **Pull:** Create incentives for industrial involvement & investment

- **Create the policies necessary for assuring global access**
## Advocacy in OECD Countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Advocacy</th>
<th>Political Support</th>
<th>Negotiations</th>
<th>Financing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>Denmark</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>France</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>Germany</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>Ireland</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>Japan</td>
<td>🌟</td>
<td></td>
<td></td>
<td>🌟</td>
</tr>
<tr>
<td>Netherlands</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>Norway</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>Sweden</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
<tr>
<td>United States</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
<td>🌟</td>
</tr>
</tbody>
</table>
## Global Expenditures on HIV Vaccines

<table>
<thead>
<tr>
<th></th>
<th>1994</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Development</strong></td>
<td>$ 20 M</td>
<td>$ 50-70 M</td>
</tr>
<tr>
<td><strong>Developing Country Specific</strong></td>
<td>$ 1-2 M</td>
<td>$ 10-20 M</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 125 M</td>
<td>$ 350-400 M</td>
</tr>
</tbody>
</table>
Estimated Worldwide HIV Expenditures*
(2001 in Millions of Dollars)

- Prevention & Care 75-80%
- Basic research, therapeutic & Other
- Vaccines $350-400M (LDC effort <$20 M)

Global Total = $20+ Billion

* Source: IAVI estimates & AIW II
SCIENTIFIC BLUEPRINT 2000:
ACCELERATING
GLOBAL EFFORTS
IN
AIDS VACCINE DEVELOPMENT
JULY
2000
Scientific Blueprint 2000
Key Recommendations

- Additional resources needed:
  - > US$ 1 billion over 7 years
- Develop & prioritize at least 25 candidate vaccines
  - Compare in Phase I/II and non-human primates
  - Goal of 6-8 efficacy trials by 2007
- Compress development timelines by at least 50%
  - Phase I/II instead of Phase I to Phase II
  - Parallel efficacy trials in multiple countries
- Industry will not do alone—need public sector input
IAVI’s new R&D model

- Virtual vaccine company
  Industrial-based project management

- Vaccine Development Partnerships
  Focus where the epidemic is most severe; work in full partnership with developing countries
The Road to an AIDS Vaccine

Basic Research

Vaccine Design

Applied Vaccine Research

Pilot manufacturing

Project management

Regulatory affairs, QA, QC

Phase I/II

Process development

International clinical trials infrastructure

Efficacy Trials

Licensed vaccine

Scale-up manufacturing
Why an Accelerated Multi-pronged Approach?

Shared Knowledge Shortens Vaccine Development Time Frames, Enhancing Likelihood of Finding a Viable Vaccine Sooner
IAVI Vaccine R&D Program
April 2001

- DNA (Kenya-clade A) Poly-epitope UK     Phase 1 enrolled
- DNA (Kenya-clade A) Poly-epitope Kenya   Phase 1 underway
- MVA (Kenya-clade A) Poly-epitope UK      Phase 1 underway
- VEE Replicon Particle (South Africa-clade C) GMP
- Single dose AAV (Uganda & SA-clade A, C&D) Design
- Oral Salmonella delivered DNA (Uganda)- clade A Design
- Multigenic MVA (India) (clade C) Design
- DNA + MVA (China - clade C) Design
- DNA+ Tiantan-Pox (China) (clade C) 2Q,2001
Targeted Genetics Stock Price, week February 14, 2000

= Announcement of IAVI-TGen agreement
IAVI Intellectual Property Negotiating Strategy

- Critical that *both* sides have needs met

- *Company*: IP rights remain with the company & they have the freedom to operate in profitable markets

- *Philanthropic*: If company does not make vaccine available to poorest populations in reasonable quantity and at reasonable cost, IAVI has the right to make other arrangements for vaccine manufacture
Social Venture Capital

- Use significant public sector investments to negotiate an Intellectual Property position. Use this IP position to ensure access rather than profit
  - Do not dilute equity or IP position

- Work with companies using all of our resources (as a VC would) to ensure their success and therefore ensure a win-win strategy
Narrow request

- R.O.W.: Markets of no or little interest. Ones which they would not serve during peak patent monopoly position anyway
- Non-exclusive & geographically restricted
- Only marching if doesn’t supply “reasonable” quantity, speed and price
- Only HIV vaccines, and only for public sector of LDCs
- Flexible—industry can define terms
Advantages for companies

- Test platform technologies
- Freedom to operate in primary, commercially attractive markets
- IAVI assistance (where appropriate) with product development, testing, regulatory submissions as well as fund raising, management, etc.
- Remove controversy as to supply of the poor
- IAVI acts as honest broker
- Good PR
Lessons

- Researchers
- Heads of R & D
- Business Development
- Lawyers
Size of Company as compared to IP complexity

Academia

Small Biotech

Medium Biotech

Big Pharma

Size

Complexity of Negotiations
Potential models for supplying the poor

- Company produces globally; price tiering
- Company produces globally; bulk packaging for South
- Company produces for OECD; joint venture for LDC provision
- Company produces for OECD; IP for LDCs stays in trust and is produced through contract manufacturing/technology transfers
- Regardless, political acceptance of price tiering, quality and no IP leakage is critical to success
Create incentives for Industrial Investment

- Active dialogue with the vaccine industry
- Policy program including political support for strongly tiered pricing
- Create credible market in developing countries through vaccine purchase funds
  - Ensure availability
  - Increase profits/reduce cost of manufacturing
  - Remove controversies related to supply for the poor
Create incentives for Industrial Investment II

- Reduce R & D costs by directly financing research & preparing for clinical testing
- Target other areas of concern to industry such as regulatory simplicity & liability
- Tax credits and sales incentives
- Active collaborative program working with World Bank, EC & individual OECD Governments
PREPARING NOW TO ASSURE ACCESS

AIDS VACCINES FOR THE WORLD:
PREPARING NOW
TO ASSURE
ACCESS
JULY 9, 2000

AN IAVI BLUEPRINT
Why Now?

Still years before having a licensed vaccine…

✓ Extraordinary complex planning required if we are to create new paradigm of N/S parallel introduction
✓ Production capacity & scale up decisions have long lead time
✓ Novel delivery systems required
✓ Moral, Political & Ethical dilemmas will need to be tackled
✓ Lessons for other problems; sides less entrenched
Access Action Plan I

- Effective pricing and global financing mechanisms to assure prompt use where they are needed.
  - Develop tiered pricing structure that enhances access by permitting poorer countries to pay what they can afford whilst permitting companies a satisfactory return on investment.
  - Create purchase and delivery mechanisms within OECD nations with immediate credible financial commitments
Features of Financing Mechanisms

- Level of financing adequate to the need - >$1B/year
- Choice for countries to allow mix & match instruments
- Incentives for early adoption of vaccine
- Efficiency & credibility
- Transparency and accountability
Financing options

- Grant fund (like GFCV)
- Leveraged grant financing (use grant funds to pay off World Bank IDA credit or use grant funds to subsidize IBRD rates)
- Enhanced loan financing with some grant component
- ALL should include purchase and distribution
Access Action Plan II

- Mechanisms must be developed to make reliable estimates of demand for specific vaccines and to ensure timely creation of production capacity to permit accelerated worldwide access
  - WHO/UNAIDS – IAVI process underway
  - World Bank – EC effort
Access Action Plan III

- Appropriate delivery systems, policies, and procedures must be developed for vaccination of adolescents, sexually active adults, and other at-risk populations
  - e.g. Hepatitis B
Access Action Plan IV

- Harmonize national regulations and international guidelines governing vaccine approval and use.

- Demonstrate to industry global commitment to effective worldwide deployment by maximizing use of one or more currently underutilized non-HIV vaccines working with GAVI.
IAVI’s Special Characteristics

- **Mandate**: Laser focus on preventive HIV vaccines
- **Customer focus**: Global put particularly developing countries
- **Mechanism**: Public-private partnerships; willing to use any instrument
- **Management**: Industrial style project management
- **Critical goal**: speed
- **Rewards**: Access rather than profit: social venture capital
- **Engagement**: Full developing country involvement
- **Style**: Full integration of communications/science
- **Financing**: Push and pull; public and private
- **Access**: Solve before licensure
IMAGINE a World Without AIDS